| 103 1.91 (1.89%) | 02-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 154.8 | 1-year : | 178.77 |
| Resists | First : | 132.53 | Second : | 153.05 |
| Pivot price | 115.07  |
|||
| Supports | First : | 99.33 | Second : | 82.64 |
| MAs | MA(5) : | 101.84 |
MA(20) : | 120.45 |
| MA(100) : | 136.95 |
MA(250) : | 126.78 |
|
| MACD | MACD : | -9.8 |
Signal : | -7.7 |
| %K %D | K(14,3) : | 5 |
D(3) : | 5.1 |
| RSI | RSI(14): 26.3 |
|||
| 52-week | High : | 156.66 | Low : | 97.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ILMN ] has closed above bottom band by 26.2%. Bollinger Bands are 167.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 103.15 - 103.73 | 103.73 - 104.26 |
| Low: | 97.82 - 98.57 | 98.57 - 99.25 |
| Close: | 100 - 101.09 | 101.09 - 102.09 |
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Wed, 19 Feb 2025
Illumina unveils first-of-its-kind spatial transcriptomics technology - Yahoo Finance
Tue, 18 Feb 2025
Strategic Financial Concepts LLC Buys New Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Tue, 18 Feb 2025
Illumina, Inc. (NASDAQ:ILMN) Sees Significant Increase in Short Interest - MarketBeat
Mon, 17 Feb 2025
Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Mon, 17 Feb 2025
Asset Management One Co. Ltd. Increases Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Mon, 17 Feb 2025
Brokerages Set Illumina, Inc. (NASDAQ:ILMN) Price Target at $159.45 - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 158 (M) |
| Shares Float | 158 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 105.2 (%) |
| Shares Short | 6,510 (K) |
| Shares Short P.Month | 5,040 (K) |
| EPS | -7.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.93 |
| Profit Margin | -28 % |
| Operating Margin | -9.7 % |
| Return on Assets (ttm) | 2.6 % |
| Return on Equity (ttm) | -30.2 % |
| Qtrly Rev. Growth | -1.7 % |
| Gross Profit (p.s.) | 18.87 |
| Sales Per Share | 27.58 |
| EBITDA (p.s.) | 4.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 837 (M) |
| Levered Free Cash Flow | 265 (M) |
| PE Ratio | -13.34 |
| PEG Ratio | 0 |
| Price to Book value | 6.86 |
| Price to Sales | 3.71 |
| Price to Cash Flow | 19.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|